Virginia G Kaklamani

  • 5776 Citations
  • 39 h-Index
19972020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Virginia G Kaklamani is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., Hayes, D. F. & 9 others, Dees, E. C., Geyer, C. E., Olson, J. A., Wood, W. C., Lively, T., Paik, S., Ellis, M. J., Abrams, J. & Sledge, G. W., Mar 2020, In : JAMA Oncology. 6, 3, p. 367-374 8 p.

Research output: Contribution to journalArticle

Open Access
  • 9 Scopus citations

    Everolimus inhibits the progression of ductal carcinoma in situ to invasive breast cancer via downregulation of MMP9 expression

    Chen, G., Ding, X. F., Pressley, K., Bouamar, H., Wang, B., Zheng, G., Broome, L. E., Nazarullah, A., Brenner, A. J., Kaklamani, V., Jatoi, I. & Sun, L. Z., Mar 15 2020, In : Clinical Cancer Research. 26, 6, p. 1486-1496 11 p.

    Research output: Contribution to journalArticle

  • Subtype-Guided 18F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study

    Wu, S., Wang, Y., Li, J., Zhang, N., Mo, M., Klimberg, S., Kaklamani, V., Cochet, A., Shao, Z., Cheng, J. & Liu, G., Apr 1 2020, In : Oncologist. 25, 4, p. e626-e633

    Research output: Contribution to journalArticle

    Open Access
  • A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

    Patel, T. A., Ensor, J. E., Creamer, S. L., Boone, T., Rodriguez, A. A., Niravath, P. A., Darcourt, J. G., Meisel, J. L., Li, X., Zhao, J., Kuhn, J. G., Rosato, R. R., Qian, W., Belcheva, A., Schwartz, M. R., Kaklamani, V. G. & Chang, J. C., Sep 2 2019, In : Breast Cancer Research. 21, 1, 100.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors

    Hanker, A. B., Kaklamani, V. & Arteaga, C. L., Apr 2019, In : Cancer Discovery. 9, 4, p. 482-491 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 19 Scopus citations